Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 20, Issue 11, Pages 1479-1496Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.2011.623697
Keywords
Ad-IFN gamma; amsilarotene; AR-726; aroplatin; ASP-0265; AZD-0530; bardoxalone; BIM-23A760; CGP-47905; CP-870893; drozitumab; efungumab; galiximab; GDC-0152; golgnerminogene pradenovac; GSK-184072; IDEC-114; JNJ-26854165; KW-2449; MYC-124; neuradiab; NRX-4204; patupilone; PF-3814735; PF-477736; PF-4929113; PF-5208766; resveratrol; RG-4733; RG-7419; RG-7425; RTA-401; saracatinib; serdemetan; SGI-1776; SRT-501; SU-14813; TAC-101; TAK-683; TAS-109; TG-1042; TNFerade
Categories
Ask authors/readers for more resources
The Pharmaceutical Industry is currently undergoing a period of rapid change as the pressures of the financial markets highlight fundamental inefficiencies in the current business model. The Achilles heel for the industry is the unacceptable level of attrition in clinical drug development. An imperative for the industry is to reduce the cost and increase the efficiency of Research and Development (R&D). This article provides an analysis of cancer drugs dropped from the industry pipeline in 2010 and offers a perspective on how the future oncology drug pipeline might evolve.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
